Aimmune Therapeutics (AIMT) Posts Earnings Results, Beats Estimates By $0.03 EPS

Share on StockTwits

Aimmune Therapeutics (NASDAQ:AIMT) announced its quarterly earnings results on Thursday. The biotechnology company reported ($0.89) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.92) by $0.03, reports.

Shares of NASDAQ:AIMT opened at $30.29 on Friday. Aimmune Therapeutics has a 12 month low of $24.56 and a 12 month high of $42.00. The stock has a market capitalization of $1.88 billion, a P/E ratio of -11.61 and a beta of -0.10.

A number of brokerages recently commented on AIMT. Credit Suisse Group set a $40.00 price target on shares of Aimmune Therapeutics and gave the company a “buy” rating in a report on Friday. BidaskClub downgraded shares of Aimmune Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, August 1st. ValuEngine raised shares of Aimmune Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, November 1st. Wedbush began coverage on shares of Aimmune Therapeutics in a report on Wednesday, October 17th. They issued a “buy” rating and a $72.00 price target for the company. Finally, Zacks Investment Research raised shares of Aimmune Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, July 24th. Three research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $50.70.

WARNING: This news story was first reported by Week Herald and is the property of of Week Herald. If you are reading this news story on another site, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The correct version of this news story can be viewed at

Aimmune Therapeutics Company Profile

Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy product candidate is AR101, an investigational biologic for the treatment of patients with peanut allergy.

Recommended Story: Growth Stocks

Earnings History for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply